SRR2932842
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.320
- G2M_CHECKPOINT+0.290
- ALLOGRAFT_REJECTION+0.280
- SPERMATOGENESIS+0.220
- MITOTIC_SPINDLE+0.180
- PROTEIN_SECRETION+0.070
- UV_RESPONSE_DN+0.070
- PANCREAS_BETA_CELLS+0.010
- ANGIOGENESIS-0.050
- BILE_ACID_METABOLISM-0.050
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- OXIDATIVE_PHOSPHORYLATION-0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.430
- MTORC1_SIGNALING-0.420
- CHOLESTEROL_HOMEOSTASIS-0.400
- FATTY_ACID_METABOLISM-0.370
- GLYCOLYSIS-0.350
- MYOGENESIS-0.350
- P53_PATHWAY-0.350
- INTERFERON_ALPHA_RESPONSE-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR627451 | GTEX | — | 0.877 |
| 2 | SRR627462 | GTEX | — | 0.877 |
| 3 | SRR627429 | GTEX | — | 0.873 |
| 4 | TCGA-DQ-7591-01A-11R-2081-07 | — | — | 0.870 |
| 5 | TCGA-BB-4223-01A-01R-1436-07 | — | — | 0.867 |
| 6 | SRR934973 | — | — | 0.864 |
| 7 | e356598b-7611-492a-98ed-ef2ec1b77b7a | — | — | 0.858 |
| 8 | TCGA-QK-A6IF-01A-11R-A31N-07 | — | — | 0.856 |
| 9 | b8135e73-31c3-49af-b4da-a7ed5f28d68a | — | — | 0.855 |
| 10 | 62454053-936d-4f19-8522-6219c47bdd1c | — | — | 0.846 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.070 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.070 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.010 | Cobimetinib | — uncovered |